R. Nash, L. Johnston, and P. Parker, A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.11, issue.7, pp.495-505, 2005.
DOI : 10.1016/j.bbmt.2005.03.006

F. Neumann, T. Graef, and C. Tapprich, Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings, Bone Marrow Transplantation, vol.15, issue.11, pp.1089-93, 2005.
DOI : 10.1038/sj.bmt.1704956

R. Van-hest, J. Doorduijn, and B. De-winter, Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients, Therapeutic Drug Monitoring, vol.29, issue.3, pp.353-60, 2007.
DOI : 10.1097/FTD.0b013e31805d8816

G. Vogelsang and S. Arai, Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings, Bone Marrow Transplantation, vol.27, issue.12
DOI : 10.1038/sj.bmt.1703076

S. Knight and P. Morris, Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review, Transplantation, vol.85, issue.12
DOI : 10.1097/TP.0b013e3181744199

A. Premaud, J. Debord, and A. Rousseau, A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.23, issue.6, pp.837-884, 2005.
DOI : 10.2165/00003088-200544080-00005

A. Premaud, L. Meur, Y. Debord, and J. , Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods, Ther Drug Monit, issue.3, pp.354-61, 2005.

L. Meur, Y. Buchler, M. Thierry, and A. , Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation, Am J Transplant, issue.11, pp.2496-503, 2007.

F. Saint-marcoux, J. Debord, and G. Hoizey, Statistics of MMF dose adjustment on ISBA, a free website for dose adjustment of immunosuppressive drugs abstract, Ther Drug Monit, vol.29, issue.4, p.241, 2007.

M. Maris, B. Sandmaier, and B. Storer, Unrelated Donor Granulocyte Colony-Stimulating Factor???Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing, Biology of Blood and Marrow Transplantation, vol.12, issue.4, pp.454-65, 2006.
DOI : 10.1016/j.bbmt.2005.12.030

I. Haentzschel, J. Freiberg-richter, and U. Platzbecker, Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation, Bone Marrow Transplantation, vol.44, issue.2, pp.113-133, 2008.
DOI : 10.1016/S0041-1345(98)01926-5

F. Larosa, C. Marmier, and R. E. , Peripheral T-cell expansion and low infection rate after reduced-intensity conditioning and allogeneic blood stem cell transplantation, Bone Marrow Transplantation, vol.33, issue.9
DOI : 10.1038/sj.bmt.1704889

K. Na-bangchang, O. Supasyndh, and T. Supaporn, Simple and sensitive high-performance liquid chromatographic, J Chromatogr B Biomed Sci Appl, issue.1, pp.169-73, 2000.

N. Zahr, Z. Amoura, and J. Debord, Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.62, issue.4, pp.277-84, 2008.
DOI : 10.2165/00003088-200847040-00005

J. Debord, E. Risco, and M. Harel, Application of a Gamma Model of Absorption to Oral Cyclosporin, Clinical Pharmacokinetics, vol.16, issue.5, pp.375-82, 2001.
DOI : 10.2165/00003088-200140050-00004

F. Saint-marcoux, C. Knoop, and J. Debord, Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.21, issue.4, pp.1317-1345, 2005.
DOI : 10.2165/00003088-200544120-00010

J. Proost and D. Eleveld, Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets, Pharm Res, issue.12, pp.2748-59, 2006.

J. Steimer, A. Mallet, and J. Golmard, Alternative Approaches to Estimation of Population Pharmacokinetic Parameters: Comparison with the Nonlinear Mixed-Effect Model, Drug Metabolism Reviews, vol.82, issue.1-2
DOI : 10.1007/BF01061210

D. Argenio and '. Dz, Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments, Math Biosci, 1990.

L. Sheiner and S. Beal, Some suggestions for measuring predictive performance, Journal of Pharmacokinetics and Biopharmaceutics, vol.61, issue.4, pp.503-515, 1981.
DOI : 10.1007/BF01060893

T. Ishibashi, Y. Yano, and T. Oguma, Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients, British Journal of Clinical Pharmacology, vol.19, issue.2, pp.205-218, 2003.
DOI : 10.1046/j.1365-2125.2003.01871.x

S. Irtan, F. Saint-marcoux, and A. Rousseau, Population Pharmacokinetics and Bayesian Estimator of Cyclosporine in Pediatric Renal Transplant Patients, Therapeutic Drug Monitoring, vol.29, issue.1, pp.96-102, 2007.
DOI : 10.1097/FTD.0b013e3180310f9d

P. Jacobson, J. Rogosheske, and J. Barker, Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation, Clinical Pharmacology & Therapeutics, vol.78, issue.5, pp.486-500, 2005.
DOI : 10.1016/j.clpt.2005.08.009

J. Huang, P. Jacobson, and R. Brundage, Prediction of Unbound Mycophenolic Acid Concentrations in Patients After Hematopoietic Cell Transplantation, Therapeutic Drug Monitoring, vol.29, issue.4, pp.385-90, 2007.
DOI : 10.1097/FTD.0b013e318074d979

J. Ng, J. Rogosheske, and J. Barker, A Limited Sampling Model for Estimation of Total and Unbound Mycophenolic Acid (MPA) Area Under the Curve (AUC) in Hematopoietic Cell Transplantation (HCT), Therapeutic Drug Monitoring, vol.28, issue.3, pp.394-401, 2006.
DOI : 10.1097/01.ftd.0000211821.73231.8a